Cartesian Therapeutics, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.47) Per Share (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Cartesian Therapeutics in a note issued to investors on Tuesday, April 23rd. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($0.47) per share for the quarter. HC Wainwright has a “Buy” rating and a $54.00 price objective on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share. HC Wainwright also issued estimates for Cartesian Therapeutics’ Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.52) EPS and Q4 2025 earnings at ($0.58) EPS.

Cartesian Therapeutics (NASDAQ:RNAC) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($0.30) by ($2.10). Cartesian Therapeutics had a negative net margin of 845.01% and a negative return on equity of 58.21%. The business had revenue of $8.27 million during the quarter.

RNAC has been the topic of a number of other research reports. Needham & Company LLC assumed coverage on Cartesian Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $42.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of Cartesian Therapeutics in a research note on Tuesday. Finally, SVB Leerink assumed coverage on shares of Cartesian Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $39.00 price objective for the company.

Cartesian Therapeutics Trading Up 12.8 %

Cartesian Therapeutics stock opened at $20.59 on Wednesday. The business’s 50 day simple moving average is $19.32. Cartesian Therapeutics has a 52-week low of $11.66 and a 52-week high of $42.60.

Insider Activity at Cartesian Therapeutics

In other news, Director Timothy A. Springer bought 21,612 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were bought at an average cost of $16.20 per share, for a total transaction of $350,114.40. Following the completion of the transaction, the director now owns 1,017,228 shares in the company, valued at $16,479,093.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders purchased 22,472 shares of company stock worth $365,981 over the last 90 days. Company insiders own 31.20% of the company’s stock.

Institutional Trading of Cartesian Therapeutics

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee bought a new stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned approximately 0.98% of Cartesian Therapeutics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 86.95% of the company’s stock.

About Cartesian Therapeutics

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.